BIT Capital’s BridgeBio Oncology BBOT Stock Holding History

BIT Capital’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,000	Closed	-$313K	–	127
2025 Q4	$313K	Buy	+25,000	New	+$303K	0.01%	92

Other funds holding BBOT

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIT Capital's BBOT Position: Q1 2026 in Review

BIT Capital sold out of BridgeBio Oncology (BBOT) in Q1 2026, closing a stake of 25,000 shares — an estimated $313K sold.

BIT Capital first reported a position in BBOT in Q4 2025 and held it in 1 quarter. The position peaked at $313K in Q4 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

BIT Capital reported no remaining BridgeBio Oncology position as of Q1 2026 after selling out during the quarter.
BIT Capital sold 25,000 BridgeBio Oncology shares in Q1 2026, an estimated $313K.
BIT Capital first reported a position in BridgeBio Oncology in Q4 2025 and held it in 1 quarter.
BIT Capital's BridgeBio Oncology position peaked at $313K in Q4 2025.
67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on BIT Capital's 13F filing for Q1 2026, filed 13 May 2026.